Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Rubius Therapeutics, Inc. (RUBY) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/28/2023 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
03/09/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/02/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
02/27/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/27/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/27/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/27/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/27/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/22/2023 RW Form RW - Registration Withdrawal Request:
02/22/2023 8-K Quarterly results
02/14/2023 SC 13G/A Flagship VentureLabs IV, LLC reports a 42.7% stake in Rubius Therapeutics, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 13.7% stake in RUBIUS THERAPEUTICS INC
02/06/2023 8-K Quarterly results
01/20/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/21/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
10/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/13/2022 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
09/13/2022 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "Rubius Therapeutics Announces Strategic Update Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT CAMBRIDGE, Mass., September 13, 2022 -- Rubius Therapeutics, Inc. , a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform. ..."
08/12/2022 8-K Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
08/01/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/14/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/24/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/22/2022 EFFECT Form EFFECT - Notice of Effectiveness:
06/08/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/08/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy